Research programme: anticancer therapeutics - BioMarin Pharmaceutical

Drug Profile

Research programme: anticancer therapeutics - BioMarin Pharmaceutical

Latest Information Update: 01 Apr 2011

Price : $50

At a glance

  • Originator LEAD Therapeutics
  • Developer BioMarin Pharmaceutical
  • Class
  • Mechanism of Action Androgen receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Prostate cancer

Most Recent Events

  • 17 Nov 2009 LEAD is exploring partnering possibilities for LT 673
  • 16 Sep 2009 Preclinical trials in Solid tumours in China (PO)
  • 16 Sep 2009 Preclinical trials in Solid tumours in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top